Targeting bacterial integration host factor to disrupt biofilms associated with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 12, Issue 4, 2013, Pages 384-389

  Gustave, Jodi E ^a   Jurcisek, Joseph A ^b   McCoy, Karen S ^a   Goodman, Steven D ^c   Bakaletz, Lauren O ^b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Airway clearance; Biofilms; Cystic fibrosis; Integration host factor; Pseudomonas aeruginosa

Indexed keywords

DEOXYRIBONUCLEASE; INTEGRATION HOST FACTOR;

ACHROMOBACTER; ADOLESCENT; ADULT; ARTICLE; ASPERGILLUS; BIOFILM; CANDIDA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISSOLUTION; ESCHERICHIA COLI; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PSEUDOMONAS AERUGINOSA; SERRATIA; SPUTUM; SPUTUM ANALYSIS; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS;

ADOLESCENT; ADULT; BIOFILMS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; INTEGRATION HOST FACTORS; MALE; MIDDLE AGED; SPUTUM; YOUNG ADULT;

EID: 84878347137     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.10.011     Document Type: Article

References (30)

1. Gustave J.E., Jurcisek J.A., Goodman S.D., McCoy K.S., Bakaletz L.O. Biofilms recovered from the sputum of CF patients contain the bacterial protein Integration Host Factor (IHF). North American Cystic Fibrosis Conference (NACFC) November 3-5 2011, [Anaheim, California].
2. Zemanick E.T., Harris J.K., Conway S., Konstan M.W., Marshall B., Quittner A.L., et al. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros 2010, 9(1):1-16.
3. Ramsey B.W. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996, 335(3):179-188.
4. Cystic Fibrosis Foundation Patient Registry 2010: Annual Data Report. Bethesda, Maryland: Cystic Fibrosis Foundation 2011.
5. Cystic Fibrosis Foundation Patient Registry 2005: Annual Data Report. Bethesda, Maryland: Cystic Fibrosis Foundation 2006.
6. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel PJ, Willey-Courand D.B., et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007, 176(10):957-969.
7. Minasian C., Wallis C., Metcalfe C., Bush A. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax 2010, 65(1):51-56.
8. Puchelle E., Bajolet O., Abely M. Airway mucus in cystic fibrosis. Paediatr Respir Rev 2002, 3(2):115-119.
9. Matsui H., Grubb B.R., Tarran R., Randell S.H., Gatzy J.T., Davis C.W., et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998, 95(7):1005-1015.
10. McPhail G.L., Acton J.D., Fenchel M.C., Amin R.S., Seid M. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic Pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr 2008, 153(6):752-757.
11. Govan J.R., Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996, 60(3):539-574.
12. de Bentzmann S., Plesiat P. The Pseudomonas aeruginosa opportunistic pathogen and human infections. Environ Microbiol 2011, 13(7):1655-1665.
13. Stuart B., Lin J.H., Mogayzel P.J. Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Paediatr Respir Rev 2010, 11(3):177-184.
14. Kosorok M.R., Zeng L., West S.E., Rock M.J., Splaingard M.L, Laxova A., et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001, 32(4):277-287.
15. Lujan A.M., Macia M.D., Yang L., Molin S., Oliver A., Smania A.M. Evolution and adaptation in Pseudomonas aeruginosa biofilms driven by mismatch repair system-deficient mutators. PLoS One 2011, 6(11):e27842.
16. Ma L., Wang S., Wang D., Parsek M.R., Wozniak D.J. The roles of biofilm matrix polysaccharide Psl in mucoid Pseudomonas aeruginosa biofilms. FEMS Immunol Med Microbiol 2012, 65(2):377-380.
17. Costerton J.W., Stewart P.S., Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science 1999, 284(5418):1318-1322.
18. Goodman S.D., Obergfell K.P., Jurcisek J.A., Novotny L.A., Downey JS., Ayala E.A., et al. Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins. Mucosal Immunol 2011, 4(6):625-637.
19. Flemming H.C., Wingender J. The biofilm matrix. Nat Rev Microbiol 2010, 8(9):623-633.
20. Swinger K.K., Rice P.A. IHF and HU: flexible architects of bent DNA. Curr Opin Struct Biol 2004, 14(1):28-35.
21. Ratjen F., Munck A., Kho P., Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010, 65(4):286-291.
22. Shah P.L., Scott S.F., Knight R.A., Marriott C., Ranasinha C., Hodson M.E. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 1996, 51(2):119-125.
23. Fuchs H.J., Borowitz D.S., Christiansen D.H., Morris E.M., Nash M.L., Ramsey B.W., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994, 331(10):637-642.
24. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168(8):918-951.
25. Ratjen F., Doring G. Cystic fibrosis. Lancet 2003, 361(9358):681-689.
26. Ratjen F., Wonne R., Posselt H.G., Stover B., Hofmann D., Bender S.W. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr 1985, 144(4):374-378.
27. Konstan M.W., VanDevanter D.R., Rasouliyan L., Pasta D.J., Yegin A., Morgan W.J., et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010, 45(12):1167-1172.
28. Abman S.H., Ogle J.W., Harbeck R.J., Butler-Simon N., Hammond K.B., Accurso F.J. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J Pediatr 1991, 119(2):211-217.
29. Rock M.J. Newborn screening for cystic fibrosis. Clin Chest Med 2007, 28(2):297-305.
30. Wang S.S., FitzSimmons S.C., O'Leary L.A., Rock M.J., Gwinn M.L., Khoury M.J. Early diagnosis of cystic fibrosis in the newborn period and risk of Pseudomonas aeruginosa acquisition in the first 10years of life: a registry-based longitudinal study. Pediatrics 2001, 107(2):274-279.